Birgitta Versluijs

160 Predictors for allo-LS TABLE 1. Overview of publications on predictors for Allo-LS in children after HCT — continued Author Study population Primary endpoint, identified Predictor Remarks Park(9) 2011 N=127, 7.7 (0.5-18.3) yr BOS/IPS: 8.7% cGVHD, p=0.002 extensive cGVHD, p=0.001 Prais(18) 2014 N=14, 14.4 (5.6-19.2) yr PFT pre- and post-HCT Decline in PFT TBI → FVC(p=0.003), FEV1(p=0.002), FEF-25-75% (p=0.02) Chi-square Small numbers Quigg(19) 2012 N=41, 12.5 (5-19) yr PFT pre- and post-HCT Decline in PFT HR-Malignancy (no CR): FEV1, FVC, TLC GVHD: RV (p=0.014) Busulfan/Cyclofosfamide conditioning: COdiffusion (p=0.02) Logistic regression Sakagushi(15) 2012 N=189, 7 (0.3-22.7) yr IPS: 9.5% HR-Malignancy ( ≥ CR3) HR 2.5(1.0-6.7), p= 0.05 Busulfan conditioning HR 3.5 (1.3-9.9), p=0.01 Sano(8) 2014 N=210, 7 (0-21) yr IPS: 6.7% Prior HCT HR 5.13 (1.5-17.4), p=0.009 aGVHD HR 4.79( 1.29-17.8), p=0.02 Srinivasan(20) 2014 N=410,13.6 (6.2-20.9) yr PFT pre-HCT Pulmonary complications (infectious 35% + BOS/IPS: 7%) No risk factors for non-infectious complications Logistic regression Table continues on next page 9